2024 CBIIC in Guangzhou on November 30 - December 2, 2024.
James Xue, Ph.D., Founder, Chairman of the Board, Director and CEO, CANbridge Pharmaceuticals Inc. Dr. Xue is the Vice Chair of the R&D committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Deputy director general of the China Alliance for Rare Disease, Deputy director of the Shanghai Foundation for Rare Disease. He has also been a member of the Leadership Council of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School, and a mentor of the TERMEER Foundation.
Dr. Xue has over 22 years of experience in medical and pharmaceutical companies. He has been a former Genzyme executive and the founding general manager of Genzyme China. He is an entrepreneur and compound manager with international vision and years of local practical experience. Established in 2012, CANbridge is a leading China-based, global rare disease-focused biopharmaceutical company committed to the research, development, and commercialization of transformative therapies.